2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
Creators
- Herrstedt, J (Researcher)1, 2
- Clark-Snow, R. (Researcher)3
- Ruhlmann, C.H. (Researcher)4, 5
- Molassiotis, A. (Researcher)6
- Olver, I. (Researcher)7
- Rapoport, B.L. (Researcher)8
- Aapro, M. (Researcher)9
- Dennis, K. (Researcher)10
- Hesketh, Paul J. (Researcher)11
- Navari, R.M. (Researcher)12
- Schwartzberg, L. (Researcher)13
- Affronti, M.L. (Project member)14, 15
-
Bošnjak, Snežana
(Project member)16
- Zilić, Ana (Project member)16
- 1. Department of Clinical Oncology, Zealand University Hospital Roskilde and Naestved, Roskilde
- 2. Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 3. Oncology Supportive Care Consultant, Overland Park, USA
- 4. Department of Oncology, Odense University Hospital, Odense
- 5. Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- 6. College of Arts, Humanities and Education, University of Derby, Derby, UK
- 7. Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia
- 8. The Medical Oncology Centre of Rosebank, Johannesburg
- 9. Genolier Cancer Center, Genolier, Switzerland
- 10. Division of Radiation Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Canada
- 11. Division of Hematology Oncology, Lahey Hospital and Medical Center, Burlington
- 12. World Health Organization, Birmingham
- 13. William N. Pennington Cancer Institute, University of Nevada, Reno School of Medicine, Reno
- 14. Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham
- 15. Duke University School of Nursing, Duke University, Durham, USA
- 16. Department of Supportive Oncology and Palliative Care, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Description
Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of
available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial.
The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015.1
This article is an update of the 2015 guidelines.
Notes (English)
ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, CH-6900 Lugano, Switzerland
E-mail: clinicalguidelines@esmo.org.
Florian Scotté, MASCC Antiemetic Study Group. E-mail:
florian.scotte@gustaveroussy.fr (F. Scotté).
Files
Herrstedt-2024--mascc-and-esmo-guideline-update-fo.pdf
Files
(555.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:0beb0020337402a1be605f5073687273
|
555.7 kB | Preview Download |
Additional details
Identifiers
- ISSN
- 2059-7029
- PMID
- 38458657
- URL
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937211/
Dates
- Available
-
2024-01-11
Software
- Repository URL
- https://zenodo.org/uploads/13142904
- Development Status
- Active